<unk>  is a common form of non-Hodgkin lymphoma (NHL) involving the mucosa-associated lymphoid tissue <unk> , frequently of the stomach, but virtually any mucosal site can be affected. It is a cancer originating from the B-cells in the marginal zone of the<unk> . The evolution of gastric<unk>  is a multistage process starting with the infection of H. pylori resulting in the recruitment of B- and T-cells and other inflammatory cells to the gastric mucosa. Genes involved in the pathogenesis of<unk>  include FOXP1 and BCL6. A characteristic feature of<unk>  is the presence of neoplastic cells within epithelial structures with associated destruction of the glandular architecture to form lymphoepithelial lesions. Most<unk> s occur among individuals of 60 years of age. Males are more commonly affected with gastric<unk>  than females.<unk>  is usually slow growing (indolent), but some can be high grade. If left untreated,<unk>  may progress to develop fever, anemia, weight loss, and large cell lymphoma. Complications of<unk>  include anemia, cachexia, obstruction, and perforation of small intestine. The prognosis is good, and the 10-year survival rate for gastric<unk>  is approximately 90% with a disease-free survival of approximately 70%. However, in rare instances,<unk>  can progress and transform into aggressive high-grade tumors, such as extranodal diffuse large B cell lymphoma (eDLBCL), whereby the 10-year survival rate drops to approximately 42%. The staging of<unk>  is based on two staging systems: Ann Arbor staging system and the TNM staging system. If the disease is limited to the stomach (which is assessed with computed tomography), then 70-80% of patients will have a complete regression on treatment with antibiotic eradication of H. pylori. The optimal therapy for<unk>  depends on the stage at diagnosis. The treatment options for early stage (localized) gastric<unk>  include antibiotic therapy, radiotherapy, chemotherapy, surgery, and monoclonal antibodies. The treatment options for advanced stage gastric<unk>  include observation, radiotherapy, chemotherapy, and monoclonal antibodies. Secondary prevention strategies following<unk>  include urease breath test, performed 4-6 weeks after completion of the course of antibiotic therapy, and endoscopy with concurrent biopsy, performed 3-6 months after the treatment is finished.
MALT lymphoma
Enteropathy-associated T-cell lymphoma
AIDS-related lymphoma
Gastric lymphoma
Hodgkin's lymphoma
Splenic marginal zone lymphoma
Follicular lymphoma
Non-Hodgkin lymphoma